Global Acetaminophen Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Acetaminophen Market is presumed to reach the market size of nearly USD 17.62 Billion by 2032 from USD 10.93 Billion in 2023 with a CAGR of 5.45% under the study period 2024-2032.

Acetaminophen is the most commonly prescribed analgesic and antipyretic for pain relief and fever management. It is also known as Paracetamol. Acetaminophen (Paracetamol) is a pain reliever produced from coal tar. It appears to be safe to use both during pregnancy and when breastfeeding. The drug is a mild analgesic used to treat headaches, arthritis, and other minor aches and pains. Acetaminophen is classified as a non-steroidal anti-inflammatory drug (NSAID) because it is commonly used to alleviate inflammatory pain. Acetaminophen is available in pills, liquid solutions, and capsules, among other forms. The medicine is safe for all age groups, including children and infants, and the typical adult dose is 500 to 1000 mg. Acetaminophen is safe in average amounts, although it might cause nausea, vomiting, and sweating if used in excess. Severe skin rashes are uncommon, although excessive doses of the medication can cause liver failure. Acetaminophen contains the active metabolites phenacetin and acetanilide, but unlike phenacetin and acetanilide, it is not carcinogenic at therapeutic doses.

MARKET DYNAMICS

The acetaminophen market is growing due to the increasing number of chronic diseases and conditions requiring daily pain relief. Increasing consumer health awareness, rising acetaminophen applications in the dye and chemical industries, and increasing doctor recommendations of acetaminophen for mild pain and fever are all driving the acetaminophen (Paracetamol) market growth. Additionally, rising technological advancements and modernization in paracetamol production, rising research and development activities in the healthcare sector, and rising emerging markets with an increasing geriatric population base will create new opportunities for acetaminophen (Paracetamol) market. However, the rising availability of many generics, intense competition, and the growing popularity of sustainable chemistry are significant factors that will obstruct market growth and further challenge the development of the acetaminophen (Paracetamol) market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Acetaminophen. The growth and trends of Acetaminophen industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Acetaminophen market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Dosage Form

Tablet
Liquid Suspension
Infusion Solution
Other Dosage Forms

By Route Of Administration

Oral
Parenteral
Other Routes Of Administration

By Application

Pain Relief & Fever
Common Cold
Headache
Abdominal Cramps

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regional Analysis

This section covers the regional outlook, which accentuates current and future demand for the Global Acetaminophen Market Report market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Acetaminophen market include Sanofi, Janssen Pharmaceuticals, Pfizer Inc., Bayer AG, Glaxo Smithkline Pharmaceuticals Ltd, Granules India Limited, Alkem Laboratories Ltd, Abbott, Lupin Ltd, Teva Pharmaceuticals USA Inc., BRISTOL-MYERS SQUIBB, B. BRAUN MELSUNGEN, Novartis AG, 10L Chemicals And Pharmaceuticals, Sun Pharmaceutical Industries Limited, Aurobindo Pharma, Hyloris Pharmaceuticals SA, Dr. Reddy'S Laboratories Ltd., Mallinckrodt (Mallinckrodt Pharmaceuticals). This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11217225

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. ACETAMINOPHEN - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Dosage Form
- 3.7.2 Market Attractiveness Analysis By Route Of Administration
- 3.7.3 Market Attractiveness Analysis By Application
- 3.7.4 Market Attractiveness Analysis By Distribution Channel
- 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL ACETAMINOPHEN MARKET ANALYSIS BY DOSAGE FORM

5.1. Overview By Dosage Form
5.2. Historical and Forecast Data Analysis By Dosage Form
5.3. Tablet Historic and Forecast Sales By Regions
5.4. Liquid Suspension Historic and Forecast Sales By Regions
5.5. Infusion Solution Historic and Forecast Sales By Regions
5.6. Other Dosage Forms Historic and Forecast Sales By Regions

6. GLOBAL ACETAMINOPHEN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

6.1. Overview By Route Of Administration
6.2. Historical and Forecast Data Analysis By Route Of Administration
6.3. Oral Historic and Forecast Sales By Regions
6.4. Parenteral Historic and Forecast Sales By Regions
6.5. Other Routes Of Administration Historic and Forecast Sales By Regions

7. GLOBAL ACETAMINOPHEN MARKET ANALYSIS BY APPLICATION

7.1. Overview By Application
7.2. Historical and Forecast Data Analysis By Application
7.3. Pain Relief & Fever Historic and Forecast Sales By Regions
7.4. Common Cold Historic and Forecast Sales By Regions
7.5. Headache Historic and Forecast Sales By Regions
7.6. Abdominal Cramps Historic and Forecast Sales By Regions

8. GLOBAL ACETAMINOPHEN MARKET ANALYSIS BY DISTRIBUTION CHANNEL

8.1. Overview By Distribution Channel
8.2. Historical and Forecast Data Analysis By Distribution Channel
8.3. Hospital Pharmacies Historic and Forecast Sales By Regions
8.4. Retail Pharmacies Historic and Forecast Sales By Regions
8.5. Online Pharmacies Historic and Forecast Sales By Regions

9. GLOBAL ACETAMINOPHEN MARKET ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook
9.2. Introduction
9.3. North America Sales Analysis
- 9.3.1 Overview, Historic and Forecast Data Sales Analysis
- 9.3.2 North America By Segment Sales Analysis
- 9.3.3 North America By Country Sales Analysis
- 9.3.4 United States Sales Analysis
- 9.3.5 Canada Sales Analysis
- 9.3.6 Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1 Overview, Historic and Forecast Data Sales Analysis
- 9.4.2 Europe By Segment Sales Analysis
- 9.4.3 Europe By Country Sales Analysis
- 9.4.4 United Kingdom Sales Analysis
- 9.4.5 France Sales Analysis
- 9.4.6 Germany Sales Analysis
- 9.4.7 Italy Sales Analysis
- 9.4.8 Russia Sales Analysis
- 9.4.9 Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1 Overview, Historic and Forecast Data Sales Analysis
- 9.5.2 Asia Pacific By Segment Sales Analysis
- 9.5.3 Asia Pacific By Country Sales Analysis
- 9.5.4 China Sales Analysis
- 9.5.5 India Sales Analysis
- 9.5.6 Japan Sales Analysis
- 9.5.7 South Korea Sales Analysis
- 9.5.8 Australia Sales Analysis
- 9.5.9 South East Asia Sales Analysis
- 9.5.10 Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1 Overview, Historic and Forecast Data Sales Analysis
- 9.6.2 Latin America By Segment Sales Analysis
- 9.6.3 Latin America By Country Sales Analysis
- 9.6.4 Brazil Sales Analysis
- 9.6.5 Argentina Sales Analysis
- 9.6.6 Peru Sales Analysis
- 9.6.7 Chile Sales Analysis
- 9.6.8 Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1 Overview, Historic and Forecast Data Sales Analysis
- 9.7.2 Middle East & Africa By Segment Sales Analysis
- 9.7.3 Middle East & Africa By Country Sales Analysis
- 9.7.4 Saudi Arabia Sales Analysis
- 9.7.5 UAE Sales Analysis
- 9.7.6 Israel Sales Analysis
- 9.7.7 South Africa Sales Analysis
- 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE ACETAMINOPHEN COMPANIES

10.1. Acetaminophen Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11. COMPANY PROFILES OF ACETAMINOPHEN INDUSTRY

11.1. Top Companies Market Share Analysis
11.2. Market Concentration Rate
11.3. Sanofi
- 11.3.1 Company Overview
- 11.3.2 Company Revenue
- 11.3.3 Products
- 11.3.4 Recent Developments
11.4. Janssen Pharmaceuticals
- 11.4.1 Company Overview
- 11.4.2 Company Revenue
- 11.4.3 Products
- 11.4.4 Recent Developments
11.5. Pfizer Inc.
- 11.5.1 Company Overview
- 11.5.2 Company Revenue
- 11.5.3 Products
- 11.5.4 Recent Developments
11.6. Bayer AG
- 11.6.1 Company Overview
- 11.6.2 Company Revenue
- 11.6.3 Products
- 11.6.4 Recent Developments
11.7. Glaxo Smithkline Pharmaceuticals Ltd
- 11.7.1 Company Overview
- 11.7.2 Company Revenue
- 11.7.3 Products
- 11.7.4 Recent Developments
11.8. Granules India Limited
- 11.8.1 Company Overview
- 11.8.2 Company Revenue
- 11.8.3 Products
- 11.8.4 Recent Developments
11.9. Alkem Laboratories Ltd
- 11.9.1 Company Overview
- 11.9.2 Company Revenue
- 11.9.3 Products
- 11.9.4 Recent Developments
11.10. Abbott
- 11.10.1 Company Overview
- 11.10.2 Company Revenue
- 11.10.3 Products
- 11.10.4 Recent Developments
11.11. Lupin Ltd
- 11.11.1 Company Overview
- 11.11.2 Company Revenue
- 11.11.3 Products
- 11.11.4 Recent Developments
11.12. Teva Pharmaceuticals USA Inc.
- 11.12.1 Company Overview
- 11.12.2 Company Revenue
- 11.12.3 Products
- 11.12.4 Recent Developments
11.13. BRISTOL-MYERS SQUIBB
- 11.13.1 Company Overview
- 11.13.2 Company Revenue
- 11.13.3 Products
- 11.13.4 Recent Developments
11.14. B. BRAUN MELSUNGEN
- 11.14.1 Company Overview
- 11.14.2 Company Revenue
- 11.14.3 Products
- 11.14.4 Recent Developments
11.15. Novartis AG
- 11.15.1 Company Overview
- 11.15.2 Company Revenue
- 11.15.3 Products
- 11.15.4 Recent Developments
11.16. 10L Chemicals And Pharmaceuticals
- 11.16.1 Company Overview
- 11.16.2 Company Revenue
- 11.16.3 Products
- 11.16.4 Recent Developments
11.17. Sun Pharmaceutical Industries Limited
- 11.17.1 Company Overview
- 11.17.2 Company Revenue
- 11.17.3 Products
- 11.17.4 Recent Developments
11.18. Aurobindo Pharma
- 11.18.1 Company Overview
- 11.18.2 Company Revenue
- 11.18.3 Products
- 11.18.4 Recent Developments
11.19. Hyloris Pharmaceuticals SA
- 11.19.1 Company Overview
- 11.19.2 Company Revenue
- 11.19.3 Products
- 11.19.4 Recent Developments
11.20. Dr. Reddy'S Laboratories Ltd.
- 11.20.1 Company Overview
- 11.20.2 Company Revenue
- 11.20.3 Products
- 11.20.4 Recent Developments
11.21. Mallinckrodt (Mallinckrodt Pharmaceuticals)
- 11.21.1 Company Overview
- 11.21.2 Company Revenue
- 11.21.3 Products
- 11.21.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies